BEIGENE LTD 12 AUGUST 2025_EN

LATEST COMPANY ANNOUNCEMENT

BeiGene, Ltd.

Nasdaq : BGNE · SEHK : 6160 · SSE : 688235

Q2 FY2025

Associate: Anne Ching

BeOne Medicines Announces Second Quarter 2025 Financial Results and Business Updates

• Second quarter total revenues increased 42% to $1.3 billion versus second quarter 2024
• Global BRUKINSA revenues increased 49% to $950 million versus second quarter 2024
• Reported diluted GAAP Earnings per American Depositary Share (ADS) of $0.84, non-GAAP diluted Earnings per ADS of $2.25
• Anticipate 20+ milestones in next 18 months across hematology and solid tumor pipeline

SAN CARLOS, Calif. – August 6, 2025 – BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the second quarter of 2025.

“Our strong second quarter performance reinforces our trajectory as a global oncology powerhouse and underscores our proven ability to deliver sustainable, long-term growth,” said John V. Oyler, Co-Founder, Chairman and CEO of BeOne. “We are executing with purpose and advancing our mission to deliver transformative medicines to more patients worldwide. BRUKINSA, the backbone of our hematology franchise, continues to set the standard as the best-in-class BTK inhibitor with the most approved indications and market leader in the US, a position earned from superior efficacy, favorable safety, and positive patient outcomes across its five indications. Building on this momentum, our two additional Phase 3 hematology assets, BCL2 inhibitor sonrotoclax and BTK CDAC BGB-16673, have the potential to further expand our franchise leadership with pivotal data readouts and new trial initiations anticipated in the near-term. At our recent Investor R&D Day, we outlined a bold path forward with more than 20 expected R&D milestones in the next 18 months. This includes potentially promising advances across our expansive solid tumor pipeline, where we are building future global franchises targeting a range of highly prevalent cancers.”

(Amounts in thousands of U.S. dollars and unaudited)

Second Quarter 2025 Financial Results

Revenue for the second quarter of 2025 was $1.3 billion, compared to $929 million in the prior-year period driven primarily by growth in BRUKINSA (zanubrutinib) product sales in the U.S. and Europe.

Product Revenue totaled $1.3 billion for the second quarter of 2025 compared to $921 million in the prior-year period. The increase in product revenue was primarily attributable to increased sales of BRUKINSA. The U.S. continued to be the Company’s largest market, with product revenue of $685 million compared to $479 million in the prior-year period. In-licensed products from Amgen and TEVIMBRA (tislelizumab) also contributed to product revenue growth.

• U.S. sales of BRUKINSA totaled $684 million in the second quarter of 2025, representing growth of 43% over the prior-year period driven primarily by robust demand growth across all indications and modest benefit due to net pricing. BRUKINSA continues to maintain its leading new patient share across the BTKi class due to its differentiated, best-in-class clinical profile. BRUKINSA sales in Europe totaled $150 million in the second quarter of 2025, representing growth of 85% compared to the prior-year period, driven by increased market share across all major European markets, including Germany, Italy, Spain, France and the UK.

• Sales of TEVIMBRA totaled $194 million in the second quarter of 2025, representing growth of 22% compared to the prior-year period.

Gross Margin as a percentage of global product sales for the second quarter of 2025 was 87.4% compared to 85.0in the prior-year period on a GAAP basis. The gross margin percentage increased due to a proportionally higher sales mix of global BRUKINSA compared to other products in our portfolio. Gross margin also benefited from cost of sales productivity improvements for both BRUKINSA and TEVIMBRA. On an adjusted basis, which does not include depreciation and amortization, gross margin as a percentage of product sales increased to 88.1% for the second quarter of 2025, compared to 85.4% in the prior-year period.

Operating Expenses

The following table summarizes operating expenses for the second quarter of 2025:

Research and Development (R&D) Expenses increased for the second quarter of 2025 compared to the prior-year period on both a GAAP and adjusted basis primarily due to advancing preclinical programs into the clinic and early clinical programs into late stage, and offset by lower development upfront and milestone fees. Upfront fees and milestone payments related to in process R&D for in-licensed assets totaled $0.5 million and $12 million in the second quarter of 2025 and 2024, respectively.

Selling, General and Administrative (SG&A) Expenses increased for the second quarter of 2025 compared to the prior-year period on both a GAAP and adjusted basis due to continued investment in global commercial expansion, primarily in the U.S. and Europe. SG&A expenses as a percentage of product sales were 41% for the second quarter of 2025, compared to 48% in the prior-year period.

Net Income/(Loss) and GAAP/Non-GAAP Earnings Per Share

GAAP net income for the second quarter of 2025 was $94 million, an increase of $215 million over the prior-year period loss, primarily attributable to revenue growth and improved operating leverage.

For the second quarter of 2025, basic and diluted earnings per share was $0.07 and $0.06 per share and $0.87 and $0.84 per American Depositary Share (ADS), respectively, compared to basic loss of $0.09 per share and $1.15 per ADS in the prior-year period.

Free Cash Flow for the second quarter of 2025 was $220 million, an increase of $425 million over the prior-year period.

For further details on BeOne’s Second Quarter 2025 Financial Statements, please see BeOne’s Quarterly Report on Form 10-Q for the second quarter of 2025 filed with the U.S. Securities and Exchange Commission.

Full Year 2025 Guidance

BeOne has updated its full year 2025 revenue guidance and maintained its expense guidance. Guidance is summarized below:

BeOne’s total revenue guidance for full year 2025 of $5.0 billion to $5.3 billion includes expectations for strong revenue growth driven by BRUKINSA’s U.S. leadership position and continued global expansion in both Europe and other important rest of world markets. Gross margin percentage is expected to be in the mid- to high-80% range due to mix and production efficiencies as compared to 2024. BeOne’s guidance for combined operating expenses on a GAAP basis includes expectations of investment to support growth in both commercial and research at a pace that continues to deliver meaningful operating leverage. Non-GAAP operating expenses, which exclude costs related to share-based compensation, depreciation and amortization expense, are expected to track with GAAP operating expenses, with reconciling items unchanged from existing practice. Operating expense guidance does not assume any potential new, material business development activity or unusual/non-recurring items.

Second Quarter Business Highlights

Core Marketed Products

BRUKINSA (zanubrutinib)

• BRUKINSA is now approved in 75 markets globally with five new or expanded reimbursements in the quarter.
• Received U.S. Food and Drug Administration (FDA) approval and a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval of a new film-coated tablet formulation for all approved indications.
• TEVIMBRA (tislelizumab)
• TEVIMBRA is now approved in 47 markets globally with 20 new reimbursements in the quarter, including in Japan, Europe and Australia.
• Received European Commission (EC) approval in combination with gemcitabine and cisplatin for the first-line treatment of adult patients with metastatic or recurrent nasopharyngeal carcinoma.
• Received EC approval for the treatment of first-line extensive-stage small cell lung cancer.
• Received a positive CHMP opinion recommending approval of TEVIMBRA in combination with platinum-containing chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment, for the treatmentof adult patients with resectable non-small cell lung cancer (NSCLC) at high risk of recurrence.
• Received FDA approval of alternative dosing regimens of 150 Q2W and 300 Q4W for the treatment of first-line gastric cancer and second-line esophageal squamous cell carcinoma.

Select Clinical-Stage Programs

Hematology

• Sonrotoclax (BCL2 inhibitor):

o Achieved acceptance of submissions in China with priority reviews for the treatment of relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and R/R mantle cell lymphoma (MCL).

o Achieved first subject enrolled in global Phase 3 trial in combination with CD20 antibody for the treatment of

R/R CLL.

• BGB-16673 (BTK CDAC):

o Received EMA PRIority MEdicines (PRIME) designation for the treatment of patients with Waldenstrom’s macroglobulinemia (WM) previously treated with a BTK inhibitor.

o Achieved first subject enrolled for global Phase 3 BGB-16673-302 trial for the treatment of R/R CLL.

o Achieved first subject enrolled for China Phase 3 BGB-16673-303 trial for the treatment of R/R/ CLL.

o Initiated enrollment of potentially registration enabling Phase 2 trial for the treatment of R/R WM.

Lung Cancer

• Tarlatamab (AMG 757):

o Achieved acceptance of BLA and priority review in China for the treatment of 3L+ small cell lung cancer

(SCLC).

o Achieved acceptance of BLA in China for the treatment of 2L SCLC.

GI Cancers

• Zanidatamab (HER2-targeting bispecific antibody): Received regulatory approval and achieved commercial launch in China for the treatment of second-line HER2-high-expression biliary tract cancer.
• Inflammation & Immunology
• BGB-45035 (IRAK4 CDAC): Achieved first subject enrolled in Phase 1b trial for the treatment of atopic dermatitis and prurigo nodularis.
• BGB-16673 (BTK CDAC): Achieved first subject enrolled in Phase 1 trial for the treatment of chronic spontaneous urticaria.

Source: Q2_2025_Earnings_Release_FINAL.pdf

COMPANY PROFILE

BeiGene, Ltd.

Nasdaq : BGNE · SEHK : 6160 · SSE : 688235

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company's clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor. It also has various preclinical programs. The company has license agreements with Ensem Therapeutics, Inc.; Shandong Luye Pharmaceutical Co., Ltd.; Shoreline Biosciences, Inc.; Nanjing Leads Biolabs, Inc.; EUSA Pharma; Assembly Biosciences, Inc.; Bio-Thera Solutions, Ltd.; Amgen Inc.; and Beijing Novartis Pharma Co., Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.

Our Mission, Vision & Values | BeiGene

BOARD OF DIRECTORS

NAME	DESIGNATION
John V. Oyler	Co-Founder, Chairman and CEO
Xiaodong Wang, Ph.D.	Co-Founder, Chairman of Scientific Advisory Board
Olivier Brandicourt, M.D.	Director
Margaret Dugan, M.D.	Director
Donald W. Glazer	Director
Michael Goller	Director
Anthony Hooper	Director
Ranjeev Krishana	Director
Michael Nuoqing Yi	Director
Alessandro Riva, M.D.	Director
Corsee Sanders, Ph.D.	Director
Shalini Sharp	Director

Leadership Team

NAME	DESIGNATION
Melika Davis	SVP & Global Head, Clinical Operations
Clare Fisher	SVP, Business Development, Licensing, and M&A (ex-China)
Tony Guo, Ph.D.	SVP, Global Statistics & Data Science
Dany Habr, M.D.	Head of Medical Affairs, North America & International Markets
Graham Hardiman	Global Head of HR
Shreya Devendra Jani	SVP, Corporate Affairs
Jaspreet Jaggi, M.D., Ph.D.	SVP and Head, Clinical Portfolio Strategy
Yang Ji	Chief Compliance Officer
Mark Lanasa, M.D., Ph.D.	SVP, Chief Medical Officer, Solid Tumors
Chan Lee	General Counsel
Kyu-Sung Lee, Ph.D.	SVP, Global Head of Technical Operations and Manufacturing
Julie Lepin	Senior Vice President and Chief Regulatory Affairs Officer
Kyoung Lim	VP of Supply Chain
Han Ma, M.D., Ph.D.	Chief Safety Officer and SVP, Global Patient Safety
Mehrdad Mobasher, M.D., M.P.H.	Chief Medical Officer, Hematology
Richard O’Keeffe	Head of Global Quality
Jurij Petrin, M.D.	Head of New Market Development
Yan Qi, Ph.D.	SVP, Head of Public Affairs
Hongyu Qian	SVP, Medical Affairs
Jason Radford	SVP, Strategy & Corporate Development
Anand Reddi	VP, Global Strategic Initiatives and Corporate Operations, Chief of Staff to the CEO
Adam Roach	VP and Head of Asia Pacific
Aaron Rosenberg	Chief Financial Officer
Michael Schoen	Strategic Advisor and Special Assistant to the CEO
Matt Shaulis	General Manager of North America
Lai Wang, Ph.D.	Global Head of R&D
Zhiwei Wang, Ph.D.	SVP, Research Head of Chemistry
Beth Wensley	SVP, Head of Portfolio and Program Management
Kimberly Wolf	SVP, Global Commercial Strategy & Operations
Xiaobin Wu, Ph.D.	President, Chief Operating Officer
Eva Yin	Chief Commercial Officer, Greater China

Leadership & Board | BeiGene

CORPORATE SOCIAL RESPONSIBILITY

BeiGene Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility, Continues Global Expansion to Deliver Medicines to More Patients Around the World

Jul 23, 2024 7:00 AM

$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines

HOPEWELL, N.J.--(BUSINESS WIRE)-- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the opening of its flagship U.S. facility in Hopewell, N.J., at the Princeton West Innovation Campus, which houses state-of-the-art biologics manufacturing capabilities and a clinical research and development center that further bolster the Company’s differentiated model as an oncology innovator. BeiGene has more than 30 molecules at clinical or commercial stage, and the 42-acre facility provides flexibility to scale production of its innovative medicines today and in the future to meet the needs of patients with cancer.

“BeiGene has experienced unprecedented global growth, and the addition of our facility at the Princeton West Innovation Campus adds manufacturing and clinical development capabilities that will further strengthen our differentiated strategy which leverages speed, efficiency and technology to advance quality medicines faster for patients,” said John V. Oyler, Co-Founder, Chairman and CEO of BeiGene. “We are proud to be a part of New Jersey’s biopharmaceutical community that is rich in research and development and manufacturing talent. We look forward to deepening our relationships with key regional research institutions as we advance our robust pipeline of next-generation hematology and solid tumor medicines and continue to emerge as a leading global oncology innovator.”

BeiGene’s $800 million investment is the culmination of a three-year project to expand the Company’s integrated manufacturing and research and development footprint in the U.S. BeiGene will create hundreds of skilled high-tech jobs at the site by the end of 2025. New Jersey is a global leader in biopharmaceutical manufacturing and R&D with nine of the top 10 R&D companies in the world having a presence in the state. New Jersey boasts one of the country’s leading biopharmaceutical manufacturing workforces, and its infrastructure and connectivity ensure access to major markets around the world.

“I am thrilled by BeiGene’s contribution to our state’s thriving biopharmaceutical sector,” said Governor Phil Murphy. “The opening of BeiGene’s flagship campus underscores our commitment to fostering innovation and creating high-tech jobs in the Garden State. We look forward to the positive impact BeiGene will have on our economy and the advancements they will bring to cancer treatment. This significant investment highlights New Jersey’s role as a global leader in pharmaceutical manufacturing, research and development. We are proud to support BeiGene’s mission to develop affordable and accessible treatments for cancer patients worldwide.”

The site features approximately 400,000 square feet of dedicated commercial-stage biologic pharmaceutical manufacturing capacity with space to expand over time, allowing flexibility as BeiGene’s pipeline continues to mature. The facility adds to BeiGene’s late-stage research and clinical development capabilities, which have enabled the Company’s fast rise to global oncology leadership. BeiGene has built one of the industry’s deepest and most compelling oncology pipelines, addressing 80 percent of the world’s cancers with innovative modalities such as targeted degraders and antibody drug conjugates (ADCs), in addition to monoclonal antibodies and traditional small molecules. The new facility builds on BeiGene’s existing capabilities, enabling the Company to produce at scale, thereby reducing costs, ensuring supply chain resiliency, avoiding global disruptions, protecting capacity and rapidly adapting to the latest innovative modalities.

“I am excited to welcome BeiGene to Hopewell Township. BeiGene’s new cutting-edge pharmaceutical facility represents a significant investment in our community’s future. The life-saving medicines made right here in Hopewell will not only enhance global cancer treatment, but will also create good-paying, high-tech jobs and strengthen our local economy,” said Hopewell Township Mayor Courtney Peters-Manning. “We look forward to the company’s continued success in Hopewell Township.”

BeiGene recognizes that human health and the health of the planet are intrinsically linked, and the Company is committed to reducing our environmental impact. For this reason, the Company has invested in sustainability measures both in the buildings and surrounding 42 acres, including a heating and cooling system that uses recycled wastewater from the onsite wastewater treatment plant for the cooling towers. The site also is solar-ready in line with our longer-term sustainability plan. More details on the facility, including multimedia assets, are available online at: https://www.beigene.com/hopewell .

Source: BeiGene Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility, Continues Global Expansion to Deliver Medicines to More Patients Around the World – NASDAQ (US) Website

Sustainability Report 2023

A Letter from Leadership

Together with our colleagues, we are pleased to share this year’s Responsible Business & Sustainability Report. In 2023, BeiGene experienced tremendous growth both internally and with our stakeholders around the globe. Firmly rooted in our Responsible Business & Sustainability focus areas and priorities, we achieved several key initiatives. These include the development of our global health equity strategy; the approval of our first Scope 1 and Scope 2 quantitative emissions-reduction goal; the evolution of our diversity, equity, inclusion, and belonging (DEI&B) strategy; the elevation of patient insights in our drug development strategy; and the launch of the BeiGene Foundation.

Embodying our value of Bold Ingenuity, our prolific internal discovery engine powered us to over 20 candidates in our clinical pipeline. Additionally, we regained global rights to TEVIMBRA® (tislelizumab), one of our cornerstone, internally developed medicines, and BRUKINSA® (zanubrutinib) received a steady stream of regulatory approvals. This year, we achieved the remarkable milestone of BRUKINSA and TEVIMBRA treating more than one million patients around the world. To continue delivering on our mission to bring the highest-quality therapies to more patients and further affirm our value of Patients First, we also developed a comprehensive Global Health Equity Strategy in 2023.

In its inaugural year, the Global Human Equity Working Group laid the foundation for BeiGene to be a leader in health equity and DEI&B in the years to come. The working group established a governance structure, defining a vision and mission for our strategy that reflect the voices and needs of patients, communities, and colleagues, and articulated where BeiGene will focus its global health equity efforts. Our advancements in bringing life-saving medicines to patients around the world are thanks to more than 10,000 colleagues across five continents. In 2023, our rapid growth and ability to attract talent resulted in an increase of 2,625 new colleagues to our diverse and global team. We also furthered our value of Collaborative Spirit and strategic focus on a culture of belonging through the introduction of our Core Competencies, enhanced mental health and well-being benefits, and a revamped DEI&B strategy designed to evolve BeiGene into a diversity-mature organization. Creating a culture that embraces responsible business while cultivating positive change in society includes how we engage with the communities in which we work and live.

In 2023, we launched the BeiGene Foundation as an independent 501(c) (3) organization to provide grants to charitable organizations aligned with the Foundation’s mission to eliminating barriers to equitable and accessible cancer care in underrepresented communities around the world. The first grant made by the BeiGene Foundation was to The Max Foundation as part of a partnership with BeiGene to provide access to BRUKINSA to patients in low- and middle-income countries. Finally, our value of Driving Excellence encompasses our continued focus in 2023 on decreasing our environmental impacts and combatting climate change.

This year, our Responsible Business & Sustainability Working Group approved our Scope 1 and Scope 2 goal to reduce emissions by 25% per unit of internally manufactured commercial product by 2026. We also completed a Scope 3 global footprint analysis and moved ahead with plans to launch a supplier engagement program, which together will lay the groundwork to establish a Scope 3 reduction goal by 2025. In addition, findings from our climate risk assessment were integrated into our enterprise risk management process. This integration will allow these considerations to inform our strategy for adapting our operations and practices to become a more resilient organization. We thank our stakeholders for their support and commitment to our mission and growth.

Our achievements over the past year are a testament to their passion and dedication to improving the lives of people across the world. As we look ahead, we anticipate numerous opportunities to expand our clinical reach, improve our commitment to operating responsibly, and further our sustainability goals. We invite you to explore this report to learn more about our Responsible Business & Sustainability commitments and our ongoing mission as a good corporate citizen and leading oncology innovator.

Read more in our Sustainability Report 2023: Responsible Business & Sustainability Reports – NASDAQ (US) Website (beigene.com)

COMPETITORS

Novo Nordisk (Nasdaq: NOVO B)

We are a global healthcare company, founded in 1923 and headquartered just outside Copenhagen, Denmark.

Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure the diseases we treat. We employ more than 69,000 people in 80 offices around the world, and market our products in 170 countries.

Who we are (novonordisk.com)

Thermo Fisher Scientific (Nasdaq: TMO)

Thermo Fisher Scientific Inc. is an American-headquartered life science and clinical research company. It is a global supplier of analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including Life Technologies Corporation, Alfa Aesar, Affymetrix, FEI Company, BD Advanced Bioprocessing, and PPD.

About (thermofisher.com)

Amgen (Nasdaq: AMGN)

Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We discover, develop, manufacture and deliver innovative medicines to help millions of patients. Amgen helped establish the biotechnology industry more than 40 years ago and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today.

Our investment in research and development has yielded a robust pipeline that builds on our existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.

Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and we are also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.

About | Amgen

CSL (ASX: CSL)

CSL is a global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat hemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses, CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 32,000 people.

We Are CSL | CSL

Gilead Sciences (Nasdaq: GILD)

For more than 35 years, we've been tackling some of the world’s greatest public health challenges, revolutionizing HIV treatment and prevention and delivering a cure for hepatitis C. Now, we're working to discover and advance therapies that offer new hope to patients impacted by diseases across our therapeutic areas of Virology, Oncology and Inflammation. At Gilead, we strive to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we deliver innovative therapies that offer new hope to those impacted by disease. We invest in world-class science and are pursuing innovation across our therapeutic areas of virology, oncology and inflammation.

Gilead Sciences: Company

Vertex Pharmaceuticals (Nasdaq: VRTX)

We strike at the core of serious diseases to change people’s lives. Bringing together the brightest minds, investing in science and taking smart risks, we go all in. For the lives we have changed and for those who are still waiting, we will never stop fighting until we discover cures. We have research and development sites and commercial offices around the world, all dedicated to bringing the next transformative treatments to people with serious diseases. Our headquarters are in Boston and London.

Vertex Pharmaceuticals | Our Company (vrtx.com)

Regeneron Pharmaceuticals (Nasdaq: REGN)

Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases and rare diseases.

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

About Regeneron Pharmaceuticals: Innovative Biotechnology

Daiichi Sankyo (TYO: 4568)

Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. We provide innovative products and services in 29 countries/regions around the world. With more than 120 years of scientific expertise, our company draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help patients. Through the outstanding knowledge and commitment of our 17,000 + employees worldwide, we create innovative new and generic medicines, and new methods of drug discovery and delivery. We share a passion for innovation, as well as compassion for the patients around the world who are in need of our medicines.

About Us - Daiichi Sankyo

Jiangsu Hengrui Pharmaceuticals (SSE: 600276)

Jiangsu Hengrui Medicine Co., Ltd. engages in the research, development, manufacture, and sale of drugs. It specializes in antineoplastic agents, surgical anesthesia drugs, features infusion, contrast agents, and cardiovascular drugs. The company's products include tablets, oral solution, and suspension of antineoplastic drugs and narcotic drugs; psychotropic substances; soft capsules; freeze-dried powder injection; powder injection; high-volume injection, including multi-layer co-extruded infusion bag, with anti-tumor drugs; small volume injections, including antineoplastic drugs, psychotropic drugs, and non-final sterilization; biological engineering products such as polyethylene glycol recombinant human granulocyte stimulating factor injection; hard capsules; granules; powder; and film and gel. The company was founded in 1970 and is headquartered in Lianyungang, China.

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (hrssd.com.cn)

Chugai Pharmaceutical Co., Ltd (TYO: 4519)

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group.

About Chugai | CHUGAI PHARMACEUTICAL CO., LTD. (chugai-pharm.co.jp)

Biogen (Nasdaq: BIIB)

Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world. Founded in 1978, Biogen has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer’s disease.

Company | Biogen

Lonza (SIX: LONN)

Lonza is one of the world’s largest healthcare manufacturing organizations, helping pharmaceutical, biotech and nutrition companies to bring their treatments to market. United by our vision to bring any therapy to life, we support our customers with a combination of technological insight, world-class manufacturing, scientific expertise, process excellence and innovation. Our work enables our customers to develop and commercialize their therapeutic discoveries, allowing their patients to benefit from life-saving and life-enhancing treatments.

Our business is structured to meet our customers’ complex needs across four divisions: Biologics, Small Molecules, Cell & Gene and Capsules & Health Ingredients. Our services and products span from supporting early-phase discovery to custom development and manufacturing of active pharmaceutical ingredients, as well as innovative dosage forms for the pharma and consumer health and nutrition industries. Our scale and resources mean that we can provide a single integrated solution to meet our customers’ complex needs.

About Us | Lonza |

Samsung Biologics (KRX: 207940)

Samsung Biologics is a fully integrated, end-to-end CDMO service provider offering seamless development and manufacturing solutions from cell line development to final aseptic fill/finish as well as laboratory testing services at every stage for biopharmaceutical products. Our facilities are all CGMP compliant with bioreactors ranging from small to large scales to serve varying client needs.

To maximize our operational efficiency and expand our capabilities in response to growing biomanufacturing demands, Samsung Biologics launched Plant 4, which will further advance the company’s standing as the world’s largest manufacturing facility at a single site—holding a 604 kL total capacity—and announced plans to construct Plant 5, which will be operational in 2025.

As a sustainable CDMO partner of choice, we are committed to on-time, in-full delivery of the products we manufacture with our flexible manufacturing solutions, operational excellence, and proven expertise.

Our DNA | Company | About Us | SAMSUNG BIOLOGICS

Agilent Technologies, Inc (S&P 500)

Agilent supports scientists in 110 countries in cutting-edge life science research; patient diagnostics; and testing required to ensure the safety of water, food and pharmaceuticals Our advanced instruments, software, consumables, and services enable our customers to produce the most accurate and reliable results as well as optimal scientific, economic, and operational outcomes.

We play a role in advancing important research and testing, with our scientists creating some of the world's most leading-edge technology and our field engineers working side by side with customers to help them maximize productivity. We bring these solutions to a variety of markets, from pharma and diagnostics to applied materials and chemicals. Together with our customers, we’re bringing great science to life.

About Agilent - Agilent

Seagen (Nasdaq: SGEN)

Seagen is a global biotechnology company that develops and commercializes transformative cancer therapies. We’re driven by a singular mission—to make a difference for people impacted by cancer.

As an industry leader in antibody–drug conjugate (ADC) technology, we pioneered the science of harnessing antibodies designed to deliver cell-killing agents to cancer cells. Three of our four approved medicines are built on this technology. We also focus our research efforts on novel targeted small molecule therapies. In addition, we are leveraging our expertise in empowered antibodies to build a portfolio of proprietary immuno-oncology agents.

Our Mission, Vision, and Values – Seagen

Illumina, Inc (Nasdaq: ILMN)

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

Illumina | Sequencing and array solutions to fuel genomic discoveries

WuXi AppTec (SSE: 603259)

As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, advanced therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the third consecutive year in 2023 and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated."

About Us | WuXi AppTec

Sun Pharmaceutical Industries Limited (BSE: 524715)

Sun Pharmaceutical Industries Ltd. (Sun Pharma) is the fourth largest specialty generic pharmaceutical company in the world with global revenues of US$ 5.4 billion. Supported by 43 manufacturing facilities, we provide high-quality, affordable medicines, trusted by healthcare professionals and patients, to more than 100 countries across the globe.

We manufacture and market a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. It includes generics, branded generics, specialty, complex or difficult to make technology-intensive products, over-the-counter (OTC), antiretrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and Intermediates. Our broad portfolio of more than 2000 high quality molecules covers multiple dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams, and liquids.

Every year, we sell over 30 billion doses covering neuro-psychiatry, cardiology, gastroenterology, anti-infectives, diabetology, oncology, ophthalmology, dermatology, urology, nephrology and respiratory among others.

About Us - Sun Pharmaceutical Industries Ltd.

BeiGene (Nasdaq: BGNE)

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company's clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor. It also has various preclinical programs. The company has license agreements with Ensem Therapeutics, Inc.; Shandong Luye Pharmaceutical Co., Ltd.; Shoreline Biosciences, Inc.; Nanjing Leads Biolabs, Inc.; EUSA Pharma; Assembly Biosciences, Inc.; Bio-Thera Solutions, Ltd.; Amgen Inc.; and Beijing Novartis Pharma Co., Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.

Our Mission, Vision & Values | BeiGene

BioNTech SE (Nasdaq: BNTX)

BioNTech is a fully integrated, global immunotherapy powerhouse. We have been working on automated and digitized processes and build continuously capabilities for specialized manufacturing, either for individualized vaccines or for large-scale products like our COVID-19 vaccine. We are also continuously evaluating ways to democratize the access to healthcare in the long-term. While BioNTech, together with its partner Pfizer, has led the global COVID-19 vaccine effort and made great strides in individualized cancer treatments, its story is just beginning. BioNTech’s portfolio contains more than 25 product candidates in clinical trials.

In pursuit of changing the treatment paradigm with individualized cancer therapies, our pipeline encompasses oncology product candidates including individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bispecific checkpoint immunomodulators, targeted cancer antibodies and small molecules.

BioNTech | Our mission: basic research in mRNA technology and improving health

Genmab (Nasdaq Copenhagen: GMAB)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

About | Genmab

Alnylam Pharmaceuticals (Nasdaq: ALNY)

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam® Pharmaceuticals

WuXi Biologics (SEHK: 2269)

WuXi Discovery Services supports clients in the discovery and development of future therapeutics. Through comprehensive discovery and technology platforms, peer-recognized scientific leadership and expertise in oncology, immunology, infectious disease, neurosciences, fibrosis, cardiovascular and metabolic disease, we work collaboratively to rapidly advance programs from target through to preclinical selection and beyond. This integration of capabilities allows a collaborative environment, enabling enhanced efficiency and productivity. We strive to continually develop and enhance our scientific capabilities and technology to maintain its industry leading position. We aim to provide outstanding services to our existing partners and to the broader discovery community.

About WuXi Biology - WuXi Biology

Argenx (Nasdaq: AGRX)

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

argenx | Homepage - Reaching Patients Through Immunology Innovation

THE INDUSTRY

Source: BeiGene, Ltd. (BGNE) Interactive Stock Chart - Yahoo Finance

The Global Biotechnology Industry Outlook - 2024

The global BioTech Industry was above average in terms of performance last year. It was full of innovations, new technologies entered the market, new approvals such as first CRISPR gene therapy, Casgevy created history. Innovations in healthcare technology kept the morales of the stakeholders high amid market volatility. The commitment of companies launching novel cell and gene therapies to revolutionize patient lives can be realized through effective preparation of the market, their products, and internal go-to-market strategies.

2024 alone is projected to see the launch of up to 21 cell therapies and 31 gene therapies. Personalized mRNA vaccines in cancer (such as melanoma, pancreas, and others) will be an emerging therapy this year.

MarketsandMarkets has identified more than 10 global trends in the entire BioTech value chain and the report Global BioTech Industry Outlook 2024 analyses the events of 2023 while exploring new opportunities in 2024.

Performance of the last year i.e. 2023

• The global biotech industry grew from USD 366.7 bn in 2022 to USD 412.2 bn in 2023, at a CAGR of 12.3%.
• Genomics was one of the hottest segments in this period, as it grew from USD 18.9 bn in 2022 to USD 19.6 bn in 2023, with the DNA sequencing segment leading the market followed by PCR techniques.
• Allogeneic cell therapy, microbiome marvels, and CRISPR- Cas9 technology were hot in many markets, especially the US. In 2023, medicine based on gene editing was approved for the first time.
• Biologics safety testing attracted stakeholders as it grew from USD 3.7 bn in 2022 to USD 4.0 bn in 2023.
• M&A in biotech was slightly low compared to previous years but still better than Medtech segments, as major players acquired companies to strengthen their drug pipelines. It started on a good note but dipped beyond Q3’23, attributed to the war in Israel, rising crude oil prices, supply chain disruptions, and market volatility, among other reasons.
• FDA and regulatory bodies in Europe, China, Australia, India, and others are taking a special interest in gene-editing therapies.
• According to HSBC data, the first half of 2023 saw investors injecting USD 2 billion into 81 seed and Series A deals for biotech companies, marking a slower pace compared to the preceding three years. The overall venture investment in the sector amounted to USD 10.6 billion across 320 deals, figures that also fall below recent levels.
• Overall, biotech attracted favorable sentiments, as companies thrive in north America and Europe. China was a confusing market, as VBP brought down the profit margins of many drug manufacturers, with further losses expected in Q4 2023 (new tenders were floated in Oct’23 and results expected in Jan’24) once the financial results are out in early 2024.

Biotechnology: Revolutionizing Healthcare from the Inside Out

Biotechnology is leading the way in the paradigm shift in healthcare by fusing cutting-edge technology with biological processes to produce game-changing solutions. This dynamic field—often shortened to "healthcare biotech"—is drastically changing the medical environment by providing never-before-seen possibilities for prevention, diagnosis, and treatment.

One of the most significant impacts of biotech in medical field lies in its ability to target diseases at their very core. Through the utilization of cells, genes, and biomolecules, scientists are creating novel treatments that target the underlying causes of diseases rather than just their symptoms. Just a few instances of the revolutionary potential of healthcare biotech include personalized cell therapies that regenerate damaged tissues or genetically engineered viruses that target cancer cells specifically.

Beyond therapy, biotech is transforming diagnostics in the medical field. Advanced genetic and molecular analysis has revealed biomarkers that enable earlier and more precise disease detection, prompt intervention, and better patient outcomes. Imagine personalized cancer screenings based on unique genetic profiles, or non-invasive blood tests that identify early indicators of Alzheimer's disease. These developments provide vital information for better informed healthcare decisions, empowering physicians and patients alike.

Moreover, personalized medicine is being made possible by the use of biotechnology in healthcare. Medical professionals are able to customize treatments and interventions to the individual needs of each patient by knowing that each patient has a unique genetic makeup and biological response. This biotech-driven strategy has great potential to reduce side effects and increase treatment efficacy, which will ultimately result in a future of truly effective and personalized healthcare.

However, navigating the exciting world of biotech in the medical field also requires careful consideration of ethical and regulatory challenges. Maintaining patient safety, equitable access, and responsible development are still of utmost importance. Following these guidelines will be essential as we delve deeper into this revolutionary field in order to fully utilize healthcare biotech for everyone's benefit.

In summary, biotechnology in healthcare is more than just a catchphrase; it's a major force behind advancement and innovation in the industry. The future of healthcare is clearly entwined with biotech advances, ranging from personalized medicine and targeted therapies to advanced diagnostics and regenerative solutions. We can give future generations a healthier future by wisely navigating the difficulties and utilizing this field's enormous potential.

Navigating the Maze: Major Players in the Global Biotechnology Industry

The global biotechnology sector, teeming with biotechnology companies (often shortened to biotech companies), is a dynamic and diverse landscape fueled by innovation and discovery. These businesses, which range from agile startups to massive pharmaceutical companies, are advancing science and medicine and influencing the direction of healthcare.

Among the major players in this biotechnology sector are established biotech companies like Amgen, Gilead Sciences, and Biogen. These seasoned professionals in the field have a vast array of approved medications and treatments, especially in the fields of immunology, oncology, and rare diseases. Their R&D pipelines are full of promising candidates, so there will always be a fresh supply of cutting-edge treatments available to patients around the globe.

Beyond established names, the biotechnology sector is buzzing with smaller, agile biotech companies known for their niche expertise and disruptive potential. These businesses frequently concentrate on particular disease categories or cutting-edge medical innovations like gene editing or personalized care. Examples are CRISPR Therapeutics, at the forefront of gene editing applications, and Moderna, a pioneer in mRNA technology. These versatile players add fuel to the innovation engine, commonly work alongside larger biotech companies to bring breakthroughs to reality.

The biotechnology sector is not limited to any one area when it comes to geography. With well-known titans like AbbVie and Amgen, North America is home to strongholds like Roche and Novo Nordisk, but Europe is truly remarkable. With businesses like BeiGene and WuXi AppTec making major advancements in R&D and drug development, Asia, and China in particular, is quickly becoming a central role. Progress in the biotechnology sector is accelerated by the global environment, which encourages healthy competition and collaboration.

Navigating the complexities of the biotechnology sector is not without its difficulties, though. Obstacles to entry and expansion can include fierce competition, intricate regulatory requirements, and the high cost of research and development, especially for smaller bio technology companies. Furthermore, cautious navigating of the ethical issues surrounding gene editing and personalized medicine is necessary to guarantee responsible development and fair access.

In spite of these obstacles, the biotechnology sector has an unquestionably bright future. Bio technology companies have the potential to completely transform healthcare by providing solutions for unmet medical needs and enhancing the lives of patients all over the world. This can be achieved through sustained technological advancements, growing collaboration, and increased investment. To fully realize the enormous potential of this rapidly expanding industry and create a healthier future for all, it will be imperative that we remain informed about the major players, new trends, and moral issues as we go forward.

Peering into the Future: Emerging Trends Driving Growth in the Global Biotech Industry

Rising trends that have the potential to completely transform healthcare are driving a recent surge in growth in the global biotechnology industry, which is teeming with innovation and discovery. These biotech trends are influencing how the medical field and patient care will develop in the future, from using artificial intelligence to its full potential to discovering the mysteries of the microbiome.

The incorporation of artificial intelligence (AI) is one of the key biotechnology trends propelling growth. Artificial intelligence (AI) algorithms are revolutionizing drug discovery by sifting through enormous datasets to find possible drug targets and quicken the development process. Envision AI-driven systems sorting through millions of compounds to determine their potential for therapeutic use, greatly cutting down on the time and expense required to introduce new medications to the market.

AI is influencing other important facets of the biotechnology industry growth in addition to drug discovery. Imagine superhuman accuracy in medical image analysis by AI-powered diagnostics, resulting in earlier and more accurate diagnosis. Alternatively, think about robotic surgery with AI assistance, which offers patients minimal invasiveness and enhanced precision. These AI-powered innovations aren't just sci-fi ideas; they're the biotechnology trends that are actively driving the sector forward.

The study of the microbiome is another emerging trend in the biotechnology sector. Our bodies are home to a complex ecosystem of bacteria that has enormous potential for diagnosing and treating a wide range of illnesses. Scientists are investigating the potential of modifying the microbiome to treat allergies, inflammatory bowel disease, and even specific types of cancer. Imagine customized probiotic regimens based on each person's distinct microbiome, opening the door for profoundly impactful biotechnology-driven solutions.

Furthermore, personalized medicine is a major biotechnology trend. Through the analysis of biomarkers and genetic composition, scientists are able to customise treatments for individual patients. The trend toward personalization has great potential to increase treatment effectiveness and reduce adverse effects. Imagine treatments for cancer that precisely target specific mutations or immune-oncology procedures that use the patient's own immune system to combat the illness. Future biotech trends point to a time when personalized healthcare will replace the current one-size-fits-all approach.

However, navigating the exciting world of emerging biotechnology trends requires careful consideration. Ensuring responsible development, equitable access, and patient safety remains paramount. As we venture deeper into this transformative field, upholding these principles will be crucial to harnessing the full potential of biotechnology for the benefit of all.

About 80% of the Forbes Global 2000 B2B companies rely on MarketsandMarkets to identify growth opportunities in emerging technologies and use cases that will have a positive revenue impact.

In conclusion, new trends like microbiome research, AI integration, and personalized medicine are driving the biotechnology industry growth and innovation going forward. Through responsible navigation of the obstacles and harnessing of the enormous potential of these developments, the industry can build a more promising future in which biotechnology-driven solutions enhance patient outcomes globally.

Source: The Global Biotechnology Industry Outlook - 2024 (marketsandmarkets.com)

Biotechnology Market Size | Share and Trends 2024 to 2034

The global biotechnology market size was USD 1.38 trillion in 2023, calculated at USD 1.55 trillion in 2024 and is expected to reach around USD 4.61 trillion by 2034, expanding at a CAGR of 11.5% from 2024 to 2034.

Biotechnology Market Size and Forecast 2024 to 2034

The global biotechnology market size accounted for USD 1.55 trillion in 2024 and is expected to reach around USD 4.61 trillion by 2034, expanding at a CAGR of 11.5% from 2024 to 2034. The North America biotechnology market size reached USD 521.02 billion in 2023.

Biotechnology Market

Key Takeaway

• North America accounted for a revenue share of 37.79% in 2023.
• Asia Pacific has generated a revenue share of 23.99% in 2023.
• By application, the bio-pharmacy segment has captured 41.73% revenue share in 2023.
• The bio-industries application segment held a 24.33% revenue share in 2023.
• By technology, the tissue engineering and regeneration segment has garnered a 19.26% revenue share in 2023.

U.S. Biotechnology Market Size and Growth 2024 to 2034

The U.S. biotechnology market size was estimated at USD 246.18 billion in 2023 and is predicted to be worth around USD 830.31 billion by 2034, at a CAGR of 11.6% from 2024 to 2034.

Based on the region, the North American region dominated the global biotechnology market with revenue share in 2023. Several factors, including the existence of important competitors, strong R&D initiatives, and high healthcare expenses, have contributed to the North America region market growth. Furthermore, a growing number of businesses operating in the region are gaining drug approvals, which is fueling market expansion.

The Asia-Pacific is estimated to hit a growth rate of over 12.4% during the forecast period. The improvement of healthcare infrastructure, clinical trial services, and supportive government regulations are all contributing to the Asia-Pacific biotechnology market growth. Moreover, the international market players are partnering actively with local companies in order to accelerate the biotechnology market’s growth.

Growth Factors

Biotechnology is a branch of science that develops or creates products by utilizing biological systems, living creatures, or elements out of them. Biotechnology now encompasses a wide range of fields such as biochemistry, genetics, and molecular biology. Every year, new technologies and products are developed in fields such as medical, agriculture, and industrial biotechnology.

Due to the rise of the biotechnology sector in developing nations such as China, Japan, and India, the market is being driven by favorable government initiatives. The government activities are aimed at streamlining the medication regulatory pathway, standardizing clinical studies, enhancing reimbursement policies, and expediting the product approval process, all of which will provide the industry with lucrative growth potential.

Furthermore, agricultural input firms are concentrating their efforts on upgrading existing technologies, such as the development of new stacked features in crops and new germplasm through breeding innovations and gene sequencing. The key market players are concentrating their efforts on bringing agricultural innovations to market in order to boost production through long-term solutions.

The rising incidences of target diseases and genetic disorders, as well as continuous technological advancements in Polymerase Chain Reaction (PCR) technologies, the development of miniaturized portable instruments, and the incorporation of robotics, as well as increased investments, funds, and grants for research activities, are driving the growth of the biotechnology market during the forecast period.

The use of genomic analytic techniques such as microbial identification and detection of genetic changes in the diagnosis of major infectious diseases like HIV, malaria, and TB and genetic abnormalities has developed rapidly over the last decade. The expansion in the global prevalence of target diseases, together with the demonstrated usefulness of Polymerase Chain Reaction (PCR) analysis in the diagnosis and estimation of disease-causing bacteria, will drive up the use of clinical diagnostic tests and will ultimately boost the growth of biotechnology market.

The rising frequency of infectious and chronic diseases as well as increased research and development investments to develop breakthrough genomic techniques such as cell based assay and polymerase chain reaction (PCR), are likely to drive significant development in emerging countries. In developing regions, the biotechnology market growth will be aided by the rise in healthcare spending, the expansion of healthcare infrastructure, and lower procedural costs of disease diagnosis techniques.

The expansion of healthcare infrastructure in emerging countries is accompanied by rapid growth of healthcare facilities and modernization. This aspect is contributing to diagnostic laboratories’ increasing demand for clinical diagnostic procedures, which is leading in higher sales and revenue growth of biotechnologies in the market.

Biotechnology is becoming more important since large amounts of data generated by techniques such as nucleic acid and protein acid sequencing require data interpretation and management for medical and future research objectives. Consequently, the biotechnology market is likely to be driven by increased demand over the forecast period.

Market Scope

Report Coverage	Details
Growth Rate from 2024 to 2034	CAGR of 2034%
Market Size in 2023	USD 1.38 Trillion
Market Size in 2024	USD 1.55 Trillion
Market Size by 2034	USD 4.25 Trillion
Largest Market	North America
Fastest Growing Market	Asia Pacific
Base Year	2023
Forecast Period	2024 to 2034
Segments Covered	Application, Technology, Region
Regions Covered	Asia Pacific, North America, Europe, Latin America, Middle East and Africa

Application Insights

Based on the application, the bio-pharmacy dominates the biotechnology market during the forecast period. The increasing prevalence of diseases is mostly responsible for the growth of the segment. Thus, the rising demand for medicines and drugs is driving the growth of the bio-pharmacy segment in the biotechnology market.

On the other hand, bio-informatics is expected to grow at a rapid pace of 12.6% during the forecast period. The rising demand for nucleic acid and protein sequencing, rising initiatives from private and government organizations, propelling the growth of proteomics and genomics , and rising research on molecular biology and drug discovery are all growth factors for the bio-informatics segment. The bio-informatics segment is predicted to increase rapidly during the forecast period as a result of the aforementioned factors.

Technology Insights

The tissue engineering and regeneration segment held the dominating share of the market in 2023. Tissue engineering and regeneration technologies are finding applications across a broad spectrum of healthcare domains, including orthopedics, cardiology, dermatology, and neurology. The versatility of these approaches in addressing diverse medical needs further strengthens their dominance in the biotechnology market. Regulatory agencies worldwide are increasingly recognizing the potential of tissue engineering and regeneration technologies and providing support for their development and commercialization. Clinical validation through successful trials and regulatory approvals has bolstered confidence in these approaches, paving the way for their widespread adoption and market dominance.

The chromatography segment is observed to grow at the fastest pace during the forecast period. Chromatography techniques offer unparalleled analytical precision, allowing biotechnologists to separate and analyze complex mixtures of biomolecules with high resolution and accuracy. This precision is crucial for various applications in biotechnology, including drug discovery, proteomics, genomics, and quality control. Chromatography techniques, particularly affinity chromatography, ion exchange chromatography, and size exclusion chromatography, are essential for protein purification in biotechnology research and production. These techniques enable the isolation and purification of target proteins from complex biological matrices, facilitating downstream applications in biopharmaceuticals, diagnostics, and research.

Source: Biotechnology Market Size to Worth Around USD 4.25 Trillion by 2033 (precedenceresearch.com)

ACQ_REF: CS/18141/20250812/181863/CHN/24/20

ACQ_AUTHOR: Associate/Anne Ching